Key Insights

Highlights

Success Rate

67% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

18.8%

3 terminated out of 16 trials

Success Rate

66.7%

-19.8% vs benchmark

Late-Stage Pipeline

31%

5 trials in Phase 3/4

Results Transparency

33%

2 of 6 completed with results

Key Signals

2 with results67% success

Data Visualizations

Phase Distribution

13Total
Not Applicable (4)
Early P 1 (1)
P 1 (1)
P 2 (2)
P 4 (5)

Trial Status

Completed6
Terminated3
Unknown3
Active Not Recruiting2
Withdrawn1
Not Yet Recruiting1

Trial Success Rate

66.7%

Benchmark: 86.5%

Based on 6 completed trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT03726307Phase 1Active Not Recruiting

Allogeneic Regulatory Dendritic Cell (DCreg) Renal Study

NCT01086904Phase 2CompletedPrimary

Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients

NCT07364123Not ApplicableNot Yet Recruiting

Kidney Transplant Immunosuppressive Therapy Adherence Trial (KITE)

NCT04218721Not ApplicableCompletedPrimary

Implementing eHealth Interventions Into Regular Clinical Practice

NCT02706678Phase 4CompletedPrimary

Efficacy and Safety Study of the Switch From Cyclosporin to Tacrolimus in Renal Transplant Recipients

NCT03797196Phase 4Active Not RecruitingPrimary

RCT Comparing Immunosuppressive Regimens in Elderly Renal Transplant Recipients

NCT04903054Phase 2Withdrawn

Selective CD28 Blockade in Renal Transplant Recipients

NCT02956005Not ApplicableTerminatedPrimary

Envarsus XR in African American Renal Transplant Recipients

NCT01318915Early Phase 1TerminatedPrimary

Research Study of ATG and Rituximab in Renal Transplantation

NCT03110406Not ApplicableUnknownPrimary

Effects of Whole-body Vibration Training on the Heart Rate Variability Cardiac in Kidney Transplantation

NCT02973464UnknownPrimary

The Strategy in the Prevention of Renal Post-transplant Cytomegalovirus Infection Among Chinese Population

NCT01859832CompletedPrimary

Validation of a Novel Diagnostic Tool for the Evaluation of Post Renal Transplant Immunosuppression: The ImmuKnow Assay

NCT00271830TerminatedPrimary

Sexual Function in Male Renal Transplant Patients

NCT00327483Phase 4UnknownPrimary

Web Based Renal Transplant Patient Medication Education

NCT00319189Phase 4CompletedPrimary

Efficacy and Safety of Nateglinide Treatment in Renal Transplant Recipients

NCT00138970Phase 4CompletedPrimary

Calcineurin Inhibitor-Free Immunosuppression in Renal Transplant Recipients at Low Immunogenic Risk

Showing all 16 trials

Research Network

Activity Timeline